Pantozol I.V. (Pantoprazole)

Pantoprazole, the active ingredient in Pantozol I.V., is a proton pump inhibitor presented as an intravenous injection for intravenous use. It reduces gastric acid secretion and is used to treat conditions such as gastroesophageal reflux disease, erosive esophagitis, peptic ulcer disease, and for stress ulcer prophylaxis in hospitalized patients.

GNH USA supplies Pantozol I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance for global healthcare providers.

Pantoprazole, administered intravenously, is used to manage acid‑related gastrointestinal disorders. - Gastroesophageal reflux disease (GERD): reduces gastric acid exposure, relieving heartburn and esophageal irritation. - Erosive esophagitis: promotes healing of damaged esophageal lining by maintaining a higher gastric pH. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence by suppressing acid secretion. - Helicobacter pylori eradication (combination therapy): enhances the effectiveness of antibiotics by creating a less acidic gastric environment. - Stress ulcer prophylaxis: prevents development of acute gastric lesions in critically ill or postoperative patients.

Intravenous pantoprazole may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Diarrhea: loose stools that may be self‑limiting. - Nausea: sensation of queasiness, sometimes accompanied by vomiting. - Injection site reactions: erythema, pain or swelling at the infusion site.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Anaphylaxis: rapid onset of hives, swelling, respiratory distress. - Hepatic enzyme elevation: increased ALT or AST indicating liver stress. - Severe electrolyte disturbance: low magnesium or potassium levels requiring monitoring.

Prior to use, clinicians should consider several precautionary measures for intravenous pantoprazole. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Elderly patients: monitor for electrolyte disturbances and renal function. - Drug interactions: review concomitant medications for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can interact with other medications, requiring careful assessment.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - Methotrexate: increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may increase serum levels. - Ciclosporin: increased exposure.